<DOC>
	<DOCNO>NCT00301938</DOCNO>
	<brief_summary>This phase I trial study side effect best dose 7-hydroxystaurosporine give together perifosine treat patient relapsed refractory acute leukemia , chronic myelogenous leukemia , myelodysplastic syndrome . 7-Hydroxystaurosporine may stop growth cancer cell block enzymes need cell growth . Drugs use chemotherapy , perifosine , work different way stop growth cancer cell , either kill cell stop divide . Giving 7-hydroxystaurosporine together perifosine may kill cancer cell .</brief_summary>
	<brief_title>7-Hydroxystaurosporine Perifosine Treating Patients With Relapsed Refractory Acute Leukemia , Chronic Myelogenous Leukemia High Risk Myelodysplastic Syndromes</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Define maximum tolerate dose recommended phase II dose UCN-01 ( 7-hydroxystaurosporine ) administer perifosine patient relapse refractory acute leukemia , chronic myelogenous leukemia , high risk myelodysplastic disorder . SECONDARY OBJECTIVES : I . Evaluate safety toxicity UCN-01 administer perifosine patient . II . Evaluate safety toxicity perifosine administer UCN-01 patient . III . Document responses patient treated regimen . IV . Observe pharmacokinetics perifosine UCN-01 administered combination . V. Study pharmacodynamics perifosine alone , UCN-01 alone , combination leukemic blast cell . OUTLINE : This multicenter , dose-escalation study 7-hydroxystaurosporine . The first patient enrol study assign arm 1 . Once maximum tolerate dose ( MTD ) determine arm 1 , subsequent patient enrol arm 2 . ARM 1 : Patients receive load dose oral perifosine every 6 hour day 1 follow maintenance dose daily day 2-28 course 1 daily day 1-28 subsequent course . Patients also receive 7-hydroxystaurosporine intravenously ( IV ) 3 hour day 4 . Cohorts 3-6 patient receive escalate dos 7-hydroxystaurosporine MTD determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . ARM 2 : Patients receive 7-hydroxystaurosporine IV 3 hour day 1 MTD determine group I . Patients also receive oral perifosine load dose every 6 hour day 4 follow maintenance dose daily day 5-28 course 1 daily day 1-28 subsequent course . In group , treatment repeat every 28 day ≥ 2 course absence disease progression unacceptable toxicity . Patients achieve complete remission ( CR ) CR incomplete hematologic recovery receive 4 additional course beyond documentation CR . Patients achieve partial remission hematologic improvement may continue treatment absence disease progression unacceptable toxicity . After completion study treatment , patient follow 30 day periodically thereafter .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Leukemia , Monocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Leukemia , Myeloid , Accelerated Phase</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Megakaryoblastic , Acute</mesh_term>
	<mesh_term>7-hydroxystaurosporine</mesh_term>
	<mesh_term>Staurosporine</mesh_term>
	<mesh_term>Enzyme Inhibitors</mesh_term>
	<criteria>Histologically cytologically confirm hematologic malignancy 1 follow type : Relapsed refractory acute myelogenous leukemia ( AML ) Patients acute promyelocytic leukemia ( 15 ; 17 ) eligible provide fail prior tretinoin arseniccontaining regimen Patients either refractory agent ( absence durable hematologic response ) OR relapse complete response duration &lt; 6 month Relapsed refractory preBcell Tcell acute lymphoblastic leukemia ( ALL ) Chronic myelogenous leukemia ( CML ) accelerate blastic phase refractory imatinib mesylate Must evidence disease progression despite continued treatment imatinib mesylate AML arise set underlying myelodysplastic syndrome ( MDS ) and/or myeloproliferative disorder ( MPD ) Secondary therapyrelated AML De novo AML preBcell Tcell ALL adult &gt; 60 year age poorrisk feature , complex ( ≥ 3 ) adverse cytogenetics The following consider adverse cytogenetic abnormality AML : 5q 7q 9q 20q abn12p +21 +8 ( 6 ; 9 ) ( 6 ; 11 ) ( 11 ; 19 ) 7 5 inv3/t ( 3 ; 3 ) abn11q23 abn17p abn21q ( 9 ; 22 ) refractory imatinib mesylate The following consider adverse cytogenetic abnormality ALL : ( 9 ; 22 ) refractory imatinib mesylate Hypodiploidy ( 4 ; 11 ) ( 1 ; 19 ) Myelodysplastic Syndromes ( MDS ) meet 1 follow criterion : Intermediate high risk ( i.e. , International Prognostic Scoring System [ IPSS ] ≥ 1.5 ) MDS refractory progress treatment azacitidine and/or decitabine Intermediate high risk ( i.e. , IPSS ≥ 1.5 ) MDS 5q cytogenetic abnormality refractory progress treatment lenalidomide , azacitidine , decitabine Intermediate 2 high risk MDS without 5q cytogenetic abnormality refractory progress azacitidine decitabine Original 5q must also refractory lenalidomide Received OR ineligible establish curative regimen , include stem cell transplantation No active CNS leukemia ECOG performance status ( PS ) 02 OR Karnofsky PS ≥ 60 % Total direct bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST/ALT ≤ 2.5 time ULN Creatinine ≤ 2 mg/dL Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month completion study treatment No hyperleukocytosis ( i.e. , WBC &gt; 30,000/mm^3 ) ( recent treatment hydroxyurea prevent impend leukostasis allow provide dose increase ≥ 1 week ) No history allergic reaction attribute compound similar chemical biologic composition UCN01 perifosine No intrinsic impair organ function No active , uncontrolled infection Infection control antibiotic allow No symptomatic cardiac disease No active ischemia EKG LVEF ≥ 40 % echocardiogram MUGA Patients history cardiac disease mediastinal radiation undergo test ventricular function No poorly control diabetes mellitus No psychiatric illness social situation would preclude give informed consent comply study requirement No HIV positivity See Disease Characteristics At least 4 week since prior cytotoxic chemotherapy ( 6 week carmustine mitomycin C ) recover At least 4 week since prior radiotherapy recover At least 4 week since prior autologous stem cell transplantation ( SCT ) At least 90 day since prior allogeneic SCT No evidence graft v host disease At least 2 week since prior immunosuppressive therapy No concurrent hematopoietic growth factor biologic agent No concurrent investigational agent , chemotherapy , radiotherapy , immunotherapy No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>